Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Hoag Health System Selects PathAI and the AISight Image Management System to Support the Transition To Digital and AI-enabled Pathology

PathAI

PathAI, a leading precision pathology company, today announced that Hoag Health System, the leading health system in the southern California region, will adopt the AISight Image Management System (IMS) as their primary platform, powering their transition to digital pathology. The transition from analog, glass-slide-based pathology to digital pathology continues to accelerate across anatomic pathology, globally. This transition is in part driven by the availability of AI pathology tools that harness machine learning (ML) algorithms to augment and assist the pathologist interpretation. “The transition to digital pathology will unlock dramatic improvements in how care is provided to Hoag’s patients. By utilizing the most advanced image management system on the market with embedded algorithms, we expect to be able to deliver faster turnaround times to our physicians, more accurate and reproducible pathologist assessments, and expand our understanding of how biomarkers can drive optimal care decisions,” said Dr. Michael Brant-Zawadzki, MD, FACR, Hoag Vice President, Research Administration, CATALiST and Addiction. AISight 1 is a cloud-native intelligent enterprise workflow solution that is used by the world's leading laboratories and research centers to power their digital pathology workflows and AI applications. It serves as a central hub for case management, image management, and best-in-class artificial intelligence tools from PathAI and third-party partners, to enable a broad spectrum of histopathology use cases. “Together with our partners, we will continue to pursue our vision to improve patient outcomes with AI-powered technology,” said Eric Walk, MD, FCAP, Chief Medical Officer, PathAI. “We are excited to partner with forward-thinking industry leaders like Hoag who embrace the science of what machine learning algorithms can offer healthcare professionals and how those learnings can augment and empower the important work of pathologists.” According to Dr. John Cupp, MD, Director of Digital Pathology, Hoag Health System and PathAI Advisor, “Hoag is particularly excited to utilize PathAI’s ArtifactDetect algorithm that can improve pathology review, specifically to address pre-analytical factors that typically would delay pathologist review, as well as applying PathAI’s quantitative IHC scoring algorithms to support complex interpretation in PDL1 and HER2.” Importantly, PathAI will collaborate with Hoag and their laboratory information system (LIS) provider to build a bi-directional integration between AISight and their Epic Beaker LIS instance to ensure a fully integrated pathologist experience. “Computational pathology promises to unlock great potential for predictive biomarkers for patients with cancer,” said Dr. David R. Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute. “This is an exciting next step in Hoag’s digital transformation as we continue to look ahead towards healthcare innovations that offer continual advancements in patient care, treatment efficacy, and overall public health outcomes.” 1 AISight is For Research Use Only. Not for use in diagnostic procedures. About Hoag Hoag is a nonprofit, regional health care delivery system in Orange County, California. Delivering world-class, comprehensive, personalized care, Hoag consists of 1,800 top physicians, 16 urgent care facilities, 11 health & wellness centers, and two award-winning hospitals. Hoag offers a comprehensive blend of health care services that includes seven institutes providing specialized services in the following areas: cancer, digestive health, heart and vascular, neurosciences, spine, women’s health, and orthopedics through Hoag’s affiliate, Hoag Orthopedic Institute, which consists of an orthopedic hospital and four ambulatory surgical centers. Hoag is the highest ranked hospital in Orange County by U.S. News & World Report and the only OC hospital ranked in the Top 10 in California, as well as a designated Magnet® hospital by the American Nurses Credentialing Center (ANCC). For more information, visit hoag.org. About PathAI PathAI is the leading precision pathology company providing software and AI-enabled solutions to all pathologist stakeholders including laboratories, research institutions, and the biopharma industry. Developed with the input of hundreds of pathologists, PathAI’s digital pathology Image Management System, AISight, is the solution of choice for laboratories transitioning to digital workflows. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. For more information, please visit www.pathai.com. Contact Details SVM Public Relations and Marketing Communications Maggie Naples +1 401-490-9700 pathai@svmpr.com Company Website https://www.pathai.com/

April 25, 2024 10:00 AM Eastern Daylight Time

ECLYPSES USHERS IN NEW ERA OF CYBERSECURITY ASSURANCE WITH FIPS 140-3 VALIDATION OF ITS CRYPTOGRAPHIC LIBRARY

Eclypses Inc.

Eclypses, a leader in end-point data protection, today announced that it has successfully secured the Federal Information Processing Standard 140-3 (FIPS 140-3) validation. The Eclypses Cryptographic Library (ECL), which acts as a key component inside its Secure MTE Technology, successfully passed a series of tests conducted by an independent NIST-accredited laboratory. Eclypses is committed to providing its global customers with the most stringently reviewed technology to ensure their users’ data is protected. Secure MTE technology protects data at the application level, and provides endpoint verification, adhering to zero trust principles. "Customers operating in a world of exponential and ever-changing cyber threats need to have trust that their enterprise and customer data is protected,” said David Gomes, chief executive officer, Eclypses. “Attaining FIPS 140-3 certification acknowledges Eclypses' relentless pursuit of excellence in data security. This certification validates our commitment to robust security protocols and paves the way for enhanced trust and reliability for our customers and partners." About FIPS 140-3 Seen as the gold standard in data security, FIPS 140-3 validation proves that Eclypses’ Cryptographic Library effectively and consistently helps the Secure MTE Technology safeguard user data, ensuring that bad actors cannot access valuable information at any point during the data transmission process. FIPS 140-3 is a U.S. government computer security standard used to approve cryptographic modules and covers a wide range of potential applications. With this validation from a National Institute of Standards and Technology (NIST) approved testing laboratory, Eclypses Cryptographic Library (ECL) is now validated. ECL houses all cryptographic algorithms used by Eclypses’ patented Secure MTE technology. Secure MTE provides true end-to-end payload protection through every aspect of a network, regardless of the configuration, and ensures that in the event of a breach, attackers cannot use the data to cause harm. This technology is an added layer of security at a low latency, complementing existing cyber security protocols with real-time speeds. FIPS 140-3 validation gives Eclypses clients confidence that its technology is built upon the highest levels of trust and reliability. “This validation signals a company has completed a strict review process and received validation from one of the most highly regarded security standards bodies in the world,” said Jefferson Dance, chief innovation officer, Eclypses. “With the FIPS 140-3 validation, Eclypses can continue to deliver data security for its finance, healthcare, retail, and critical infrastructure clients.” In order to achieve FIPS 140-3 validation, cryptographic modules are subject to testing by NVLAP-accredited Cryptographic and Security Testing laboratories. The validation for Eclypses was performed by Penumbra Security, Inc. About Eclypses Eclypses sets the new standard for protecting the world’s most sensitive enterprise and customer data. Secure MTE® Technology delivers a transformative cyber security solution by replacing actual data with instantly obsolete, meaningless random streams of values. Even as threat vectors increase and network breaches proliferate, sensitive data is protected for its intended recipients and use. Eclypses was named Best Cybersecurity Solution in the FTF News Technology Innovations Awards in 2022 and 2023. For more information, please visit www.eclypses.com. Contact Details Racepoint Global Anna Halstead +1 617-624-3212 eclypses@racepointglobal.com

April 25, 2024 09:03 AM Eastern Daylight Time

MariMed closes acquisition of a dispensary in Illinois marking the company’s 5th in that state

MariMed Inc

MariMed CEO Jon Levine joined Steve Darling from Proactive to to share the Company’s significant developments, including its recent of Allgreens Dispensary, LLC, which closed on April 9, 2024. The acquisition enabled the Company to operate its 5th Thrive-branded dispensary in Illinois. It followed the recent opening of the Company’s processing facility in Mt. Vernon, Illinois, which enabled the Company to distribute its portfolio of top-selling brands throughout the high-growth state. Illinois surpassed $1.6 billion in adult-use cannabis sales last year, and MariMed looks to continue expanding there as current regulations in Illinois permit operators to own up to 10 dispensaries. In addition to its expansion efforts in Illinois, MariMed has acquired the assets of Our Community Wellness & Compassionate Care Center in Prince George's County, Maryland. This acquisition marks MariMed's second adult-use Thrive Wellness dispensary in Maryland, complementing its existing location in Annapolis. The Company is vertically integrated in Maryland, with a cultivation and processing facility in Hagerstown that distributes MariMed products state-wide. As a company dedicated to developing and distributing great brands and delivering an exceptional customer experience at its retail stores, these recent acquisitions underscore MariMed's commitment to strategic expansion and enhancing its footprint in key cannabis markets. Contact Details Proactive North America Proactive North America +1 604-688-8158 na-editorial@proactiveinvestors.com

April 24, 2024 02:01 PM Eastern Daylight Time

Video

Nevis Brands announces major shots are now for sale in dozens if dispensaries in Missouri

Nevis Brands

Nevis Brands CEO John Kueber joined Steve Darling from Proactive to announce the successful completion of the initial production run of Major shots in Missouri through its licensee, Stash House Distro. This milestone marks the expansion of Nevis Brands' product offerings into the Missouri market, with three flavors of its 2-ounce Major shots—Fruit Punch, Blackberry Lemonade, and Blueberry—now available for sale. Nevis Brands has previously introduced these products in Washington and Ohio, achieving successful distribution. The Major shots are infused with 100mg of THC and leverage a proprietary formula of flavor and emulsion technology, enabling rapid onset effects in under 20 minutes with minimal cannabis taste. The products are now accessible to consumers in numerous dispensaries across Missouri, further solidifying Nevis Brands' presence in the cannabis beverage market. Additionally, Kueber shared news regarding the restructuring of the company's Promissory Note due to SoRSE Technology Corp., which was initially part of Nevis Brands' purchase of the SoRSE Technology business units "THC Essentials," including the Major brand. Under the revised terms of the agreement, Nevis Brands will pay USD $100,000 by April 30th, 2024, and proceed with periodic payments to retire the note principal by December 31, 2024. This strategic move reflects Nevis Brands' commitment to managing its financial obligations while continuing to expand its product portfolio and market presence. Contact Details Proactive North America +1 604-688-8158 NA-editorial@proactiveinvestors.com

April 24, 2024 01:57 PM Eastern Daylight Time

Video

Creo Medical says NHS case study reveals significant efficiencies from Speedboat technology

Creo Medical Group PLC

Creo Medical Group PLC (AIM:CREO) CEO Craig Gulliford discusses an NHS case study that showcases the efficacy of Creo's Speedboat technology. In an interview with Proactive's Stephen Gunnion, Gulliford discussed the case study, which was conducted by the NHS Supply Chain responsible for the procurement of devices and consumables worth approximately £4 billion. This study, which analysed 130 cases, demonstrated significant cost savings and clinical outcomes, with almost £700,000 saved and reductions in hospital stay times for patients, which potentially impacts surgical and endoscopy waiting lists significantly. Gulliford also outlined future plans involving routine guidance by NICE and ongoing partnerships with the NHS Supply Chain to further implement and leverage the technology across UK trusts. He emphasized the dual benefits of clinical excellence and cost savings. Additional updates from Gulliford included progress in other areas of the company, like advancements with robotics and polymeric technology, and significant regulatory developments. Overall, these initiatives are part of Creo’s strategy to expand its product range and increase utilisation of its technology not just in the UK but globally, he added. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 24, 2024 10:56 AM Eastern Daylight Time

Video

ANGLE partners with AstraZeneca in groundbreaking oncology contract

ANGLE PLC

ANGLE PLC chief executive Andrew Newland joins Proactive's Stephen Gunnion with news the company has entered a significant contract with AstraZeneca, marking its second major collaboration with a large pharmaceutical company. Newland, expressed enthusiasm about this development, noting the contract's potential to expand ANGLE's services in oncology trials. The initial phase of the contract is valued at £150,000, but it holds substantial potential due to the possibility of implementing a new assay in numerous cancer trials involving AstraZeneca. The scope of the collaboration includes the development of assays for examining proteins on cancer cells across multiple trials, with potential earnings of £2,000 per time point in over 460 trials. The contract also enables ANGLE to further validate and possibly expand its FDA approvals, positioning it uniquely as a provider of comprehensive diagnostic solutions internationally. Looking ahead, the successful execution of the contract could lead to extensive financial gains for ANGLE PLC, ranging into the tens or even hundreds of millions of pounds, particularly as AstraZeneca's trials progress and its drugs approach commercial launch. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

April 24, 2024 10:52 AM Eastern Daylight Time

Video

Shareholder to Return to Berkshire Hathaway Annual Meeting One Year After Arrest in Omaha

NLPC

As the annual meeting for Berkshire Hathaway Inc. on May 4 in Omaha approaches, National Legal and Policy Center Chairman Peter Flaherty plans a return to the same stage where last year, while presenting NLPC’s shareholder proposal, Warren Buffett cut off his speech and Flaherty was arrested. Trumped-up charges against Flaherty were later dropped. NLPC has another proposal on Berkshire’s 2024 proxy statement and Flaherty is scheduled to speak on the measure for his allotted five minutes. The nonprofit corporate watchdog released a short video that briefly recounts last year’s incident and points out Mr. Buffett’s contradictory positions on how he manages shareholder meetings. The video may be found on NLPC’s website: https://nlpc.org/corporate-integrity-project/video-nlpc-returns-to-berkshire-hathaway-annual-meeting-one-year-after-chairmans-arrest/ The video highlights a past statement Mr. Buffett made to CNBC. Responding to an interviewer’s question about Berkshire allowing investors who attend the popular annual meeting to ask any question they want, Mr. Buffett responded, “We’ve got a partnership feeling toward the people who have given us their money, and we don’t screen ‘em, and they can ask whatever’s on their mind.” However, last year Mr. Buffett made an exception to that principle when Peter Flaherty – during his official remarks presenting NLPC’s shareholder proposal, which was on the meeting agenda – brought up Mr. Buffett’s relationship with billionaire Bill Gates, their shared philanthropic efforts, and Mr. Gates’s troubling relationship with deceased pedophile Jeffrey Epstein. At that point, Flaherty’s microphone was silenced, and security and Omaha law enforcement forcibly walked him out of the arena and to a local police precinct, where he was arrested, booked, fingerprinted and held for about three hours. As NLPC argued last year in a report to the Securities and Exchange Commission, Berkshire’s identity is inextricably linked with Mr. Buffett’s. As such, his philanthropic activities and personal associations are fair targets for criticism, unlike those of nearly any other corporate Chairman/CEO. NLPC also filed a complaint with the SEC late last year over Berkshire’s inappropriate treatment of Flaherty at the meeting. “Warren Buffett boasts that shareholders can ask questions on any topic they desire, but I guess that doesn’t include questions about Bill Gates or Jeffrey Epstein,” Flaherty said. This year’s shareholder proposal addresses concerns about Berkshire’s risk vulnerabilities over the amount its sales and supply chain depend on China. Subsidiaries such as Duracell and Fruit of the Loom, and significant investments such as Apple and Coca-Cola, substantially depend on access to the communist nation. NLPC also filed a proxy memo with the SEC in support of this year’s proposal. The video released by NLPC concludes by wondering if Mr. Buffett will keep his word, and let all Berkshire investors say “whatever is on their mind.” For more information or to schedule an interview with Paul Chesser, contact Dan Rene at 202-329-8357 or drene@nlpc.org. Please visit http://www.nlpc.org. Founded in 1991, the National Legal and Policy Center promotes ethics in public life through research, investigation, education and legal action. Contact Details National Legal and Policy Center Dan Rene +1 202-329-8357 drene@nlpc.org Company Website http://www.nlpc.org

April 24, 2024 09:00 AM Eastern Daylight Time

As the Use of AI In Healthcare Grows, Cardio Diagnostic Is Using It In Quest to Help Prevent Cardiovascular Disease

Cardio Diagnostics Holdings, Inc

By Faith Ashmore, Benzinga In the United States, one person dies from cardiovascular disease every 33 seconds, and nearly one in every four deaths is attributed to heart disease. It is the leading cause of death for men, women and people of most racial and ethnic groups across the board. In 2021, cardiovascular disease cost the U.S. approximately $219 billion and those numbers are only expected to go up if nothing changes. Fortunately, many of the deaths associated with heart disease are preventable if health professionals are able to leverage modern technology to educate and treat effectively. The Global Burden of Disease (GBD) study and the Global Burden of Cardiovascular Diseases Collaboration have provided valuable perspectives on the urgency of developing comprehensive strategies to address these risks and enhance public health. According to Gregory A. Roth, MD, MPH, the senior author of the paper, associate professor in the Division of Cardiology, and director of the Program in Cardiovascular Health Metrics at the Institute for Health Metrics and Evaluation at the University of Washington, "Cardiovascular diseases continue to pose a persistent challenge, resulting in a significant number of premature and preventable deaths." Combining advanced clinical diagnostic solutions with digital health, Artificial Intelligence (AI) and value-based care initiatives can accelerate how organizations tackle cardiovascular disease. How AI Can Be Instrumental In The Fight Against Heart Disease In 2023, the market for AI in healthcare was forecasted to reach $20.65 billion, and it is predicted to reach $187.95 billion by 2030. This is not surprising to most because the implementation of AI in healthcare has brought about a transformative shift in the industry, enabling a personalized approach to patient care. AI algorithms can effectively handle and analyze extensive medical data, including epigenetic, genetic information and DNA-based biomarkers. Healthcare providers now have the capability to make precise and personalized treatment choices, taking into account an individual's specific biology, which ultimately enhances patient outcomes. By utilizing AI-powered systems, patterns can be identified, potential health issues can be predicted, and real-time monitoring can be conducted, facilitating early intervention and preventive measures. Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an artificial intelligence-powered precision cardiovascular medicine company, is one company leading the charge in developing solutions to combat cardiovascular disease. Both the mission and capabilities of Cardio Diagnostics align with the healthcare sector's demands for leveraging cutting-edge molecular and AI technologies to drive preventive care, earlier disease detection, and chronic disease management. By employing AI and machine learning, the company can help empower healthcare providers to proactively identify high-risk populations and intervene early, leading to enhanced health outcomes and cost reductions across a broad spectrum of organizations. How The Use of Telemedicine Is Making Care More Accessible To All Communities COVID-19 dramatically changed the landscape of telehealth, and four years after the pandemic began, it looks like telehealth is here to stay. In 2023, MGMA Stat did a poll with medical group leaders to get an understanding of the current landscape of telehealth – 45% believed telehealth demand would remain mostly the same, while 27% of respondents said they expected an increase. Telemedicine capabilities have been especially helpful in rural areas that had been experiencing physician shortages before the pandemic. In rural communities, Cardio Diagnostics makes specialty cardiovascular care accessible. The divide between urban and rural healthcare options can be bridged by deploying innovative solutions. When provider organizations and employers in rural settings adopt Cardio’s solutions, which couple telehealth to advanced AI-powered DNA tests, they can drive access to highly accurate diagnostics without extensive travel or the need for specialized infrastructure. The company's solutions enhance accessibility and convenience while optimizing specialty care for patients in underserved communities where travel distances and limited access to healthcare facilities present roadblocks to timely medical attention. Cardio Diagnostics empowers healthcare organizations by enabling primary care physicians to identify cardiovascular risk and status upstream before specialty cardiology becomes necessary, ultimately delivering value-based care. The Future Of Healthcare As cardiovascular disease remains a major concern for doctors and families, modern technology must evolve how we approach prevention and treatment. Companies like Cardio Diagnostics are key to bringing AI into the fold while using digital health technologies such as telemedicine to expand healthcare possibilities and provide value-based care. Featured photo by National Cancer Institute on Unsplash. Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The Company was formed to further develop and commercialize clinical tests by leveraging a proprietary Artificial Intelligence (AI)-driven Integrated Genetic-Epigenetic Engine (“Core Technology”) for cardiovascular disease to become one of the leading medical technology companies for improving prevention, detection, and treatment of cardiovascular disease. For more information, please visit www.cardiodiagnosticsinc.com. Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," “goal,” or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, regulatory matters, protection of technology, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Current Report on Form 10-K for the period ended December 31, 2022 and Form 10-Q for the period ended March 31, 2023, under the heading “Risk Factors” in Part I, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Gene Mannheimer - Investor Relations +1 855-226-9991 investors@cardiodiagnosticsinc.com Company Website https://cardiodiagnosticsinc.com/

April 24, 2024 08:30 AM Eastern Daylight Time

Image

90% Of Americans Believe We Are Experiencing A Mental Health Care Crisis – Elevate Health And Wellness Is Providing Relief

Benzinga

By Faith Ashmore, Benzinga While the mental health crisis has been slowly brewing for decades, the global pandemic truly shined a spotlight on how many millions of Americans are struggling with mental health. Since the onset of the pandemic, 38% more Americans are participating in mental health care treatment of some kind, whether that be inpatient or outpatient services. Meanwhile, a recent poll done by CNN and the Kaiser Family Foundation showed that an overwhelming majority of Americans, roughly 90%, believe we are currently experiencing a mental health care crisis. The mental healthcare space is experiencing spikes in multiple different areas. One of the more concerning areas that are alarming professionals and the public alike is how youth mental health continues to worsen. In 2021, more than 4 in 10 students felt persistently sad or hopeless, with more than 1 in 5 students seriously considering attempting suicide. Serious mental health diagnoses and rates of addiction have also seen an uptick in recent years. In 2022, the CDC reported 105,454 drug overdose deaths, which was more than double the number from 2015 and a fivefold increase from 2002. Many of these overdoses were among middle-aged men, where an epidemic of loneliness has been reported. Now, more than ever, there is a need for high-quality mental healthcare facilities that can be a beacon of hope for millions of Americans. How Elevate Health And Wellness Is Revolutionizing The Health Care Industry Elevate Health and Wellness is a dual-licensed outpatient clinic that specializes in mental health and addiction treatment for adolescents and adults in Westport, CT; it provides unique in-person visits and electronic communication software in-between visits. The company’s mission is to provide accessible, compassionate and comprehensive treatment services, and, differentiating it from many competitors, the company has made accepting insurance a key part of its platform. The lack of insurance accepted at inpatient services has historically been a barrier to entry for people who need help and are in a vulnerable position. The clinic offers a range of in-network services that include outpatient detoxification, medication evaluation and management, individual and family psychotherapy, ADHD evaluation and testing, therapy services, and intensive outpatient programs for adolescents and adults. While many inpatient services do not have a full ecosystem that includes outpatient services, Elevate prides itself on its comprehensive approach to mental health care. The company services over 3,000 patients through its outpatient services and has virtual software to help connect patients to treatment providers with ease. Elevate's cohesive interdisciplinary team of psychiatrists, clinical psychologists, and licensed psychotherapists ensures that every patient receives quality care. The company looks at mental healthcare from a holistic approach and provides nutrition and fitness programs as well as primary care opportunities to ensure that patients have the tools necessary to live healthy and happy lives. Elevate is also in the process of obtaining a Certificate of Need (CON) for a new location in Clinton, Connecticut. This expansion aims to meet the growing need for inpatient residential facilities for adult and adolescent populations struggling with mental illness or co-morbid disorders. As Americans grapple with the ongoing mental health care crisis, companies like Elevate are champions for those who are struggling. Featured photo by Anthony Tran on Unsplash. Benzinga is a leading financial media and data provider, known for delivering accurate, timely, and actionable financial information to empower investors and traders. This post contains sponsored content. This content is for informational purposes only and not intended to be investing advice. Contact Details Benzinga +1 877-440-9464 info@benzinga.com Company Website http://www.benzinga.com

April 24, 2024 08:25 AM Eastern Daylight Time

Image

1 ... 37 38 39 40 41 ... 306